Contrast Media Use in the Operating Room

Journal of Perianesthesia Nursing

Volumn 25, Issue 2, 2010, Pages 94-103

  Bickham, Peggy ^a   Golembiewski, Julie ^a  

^a NONE

Author keywords

contrast media; postanesthesia care; surgery

Indexed keywords

CONTRAST MEDIUM;

ARTICLE; OPERATING ROOM; PERIOPERATIVE NURSING; RISK FACTOR;

CONTRAST MEDIA; OPERATING ROOMS; PERIOPERATIVE NURSING; RISK FACTORS;

EID: 77949894172     PISSN: 10899472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jopan.2010.01.013     Document Type: Article

References (38)

1. Federal Food, Drug, and Cosmetic Act, Sec. 201. (21 U.S.C. 321), Chapter II (Definitions). July 13, 2009. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChaptersIandIIShortTitleandDefinitions/ucm086297. Accessed November 30, 2009.
2. American College of Radiology; ACR Committee on Drugs and Contrast Media. Manual on Contrast Media, Version 6.0 (2008), American College of Radiology, Reston, VA
3. GE Healthcare. Omnipaque (iohexol) injection (product insert). Princeton, NJ: GE Healthcare. Revised September 2007.
4. Brown JJ. Implementing medication management standards for contrast media. Contrast agents-an overview. Presented at the 41st ASHP Mid-Year Clinical Meeting, Anaheim, California, December 3, 2006. Available at: http://www.ashp.org/DocLibrary/Policy/ContrastMedia/Contrast-Media.pdf. Accessed February 19, 2010.
5. Institute for Safe Medication Practices. Intrathecal Injection of Ionic Contrast Media May Be Fatal. Medication Safety Alert, November 27, 2003. Available at: http://www.ismp.org/Newsletters/acutecare/articles/20031127.asp?ptr=y. Accessed November 13, 2007.
6. Bourin M., Joliet P., and Ballereau F. An overview of the clinical pharmacokinetics of x-ray contrast media. Clin Pharmacokinet 32 (1997) 190-193
7. Deray G. Dialysis and iodinated contrast media. Kidney Int 69 (2006) S25-S29
8. Barrett B.J., and Parfrey P.S. Preventing nephropathy induced by contrast medium. N Engl J Med 354 (2006) 379-386
9. Phillips B.D., and Hennessey J.V. Iodinated contrast prior to evaluation for thyrotoxicosis. J Hosp Med 4 (2004) 285-288
10. European Society of Urogenital Radiology. ESUR Guidelines on Contrast Media, Version 6, 2007. Available at: http://www.esur.org/ESUR_Guidelines.6.0.html. Accessed November 30, 2009.
11. GE Healthcare. Visipaque (iodixanol) injection (product insert). Princeton, NJ: GE Healthcare. Revised April 2008.
12. Thomsen H. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR 181 (2003) 1466-1471
13. Wong G.T.C., and Irwin M.G. Contrast-induced nephropathy. Br J Anaesth 99 (2007) 474-483
14. Goldenberg I., and Shlomi M. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventative strategies. Can Med Assoc J 172 (2005) 1461-1471
15. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. Accessed March 12, 2008.
16. Navaneethan S.D., Singh S., Appasamy S., et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Am J Kidney Dis 53 (2009) 617-627
17. Briguori C., Airoldi F., D'Andrea D., et al. Renal insufficiency following contrast media administration trial (REMEDIAL): A randomized comparison of 3 preventative strategies. Circulation 115 (2007) 1211-1217
18. Solomon R, Deray G (Consensus panel for CIN). How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int. 2006;69:S51-S53.
19. Solomon R.J., et al. Cardiac angiography in renally impaired patients (CARE) study. Circulation 115 (2007) 3189-3196
20. Barrett B.J., Katzberg R.W., Thomsen H.S., et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: A double-blind comparison of iodixanol and iopamidol (The IMPACT Study). Invest Radiol 41 (2006) 815-821
21. Solomon R., Briguori C., and Bettman M. Selection of contrast media. Kidney Int 69 (2006) S39-S45
22. National Kidney Foundation. Guideline 2: Coronary artery disease. Am J Kidney Diseases 45 Suppl 3 (2005) S18-S20
23. Anderson J.L., et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 50 (2007) e112
24. McCullough P.A., et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48 (2006) 692-699
25. Jo S.H., et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography (RECOVER) study. J Am Coll Cardiol 48 (2006) 924-930
26. Solomon R.J., Mehran R., et al. Contrast-induced nephropathy and long-term adverse events: Cause and effect?. Clin J Am Soc Nephrol 4 (2009) 1162-1169
27. Sharma S.K. Iodinated contrast media and contrast-induced nephropathy: Is there a preferred cost-effective agent?. J Invasive Cardiol 20 (2008) 245-248
28. Coakley F.V., and Panicek D.M. Iodine allergy: An oyster without a pearl?. AJR 169 (1997) 951-952
29. Brockow K. Contrast media hypersensitivity-scope of the problem. Toxicology (2005) 189-192
30. Delaney A., Carter A., and Fisher M. The prevention of anaphylactoid reactions to iodinated radiological contrast media: A systematic review. BMC Med Imag 6 (2006) 2
31. Spinosa D.J., Kaufmann J.A., and Hartwell G.D. Gadolinium chelates in angiography and interventional radiology: A useful alternative to iodinated contrast for angiography. Radiology 223 (2002) 319-325
32. Rieger J., Sitter T., Toepfer M., et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17 (2002) 824-828
33. Nyman U., Elmstahl B., Leander P., et al. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?. Radiology 223 (2002) 311-318
34. Briguori C., Colombo A., Airoldi F., et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheterization and Cardiovascular Interventions 67 (2006) 175-180
35. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
36. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243 (2007) 148-157
37. Broome D.R., Girguid M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR 188 (2007) 586-592
38. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362